[Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting].
OBJECTIVE
The second generation tyrosine kinase inhibitors (TKI, dasatinib and nilotinib) used in chronic myeloid leukemia (CML) treatment have shown a benefit compared to imatinib in responses achieved and disease progression. However, both have been related to some cardiovascular toxicity, being more frequent in patients with cardiovascular risk factors (CVRFs). Nowadays, due to the lack of recommendations for CML patients, CVRF management is carried out heterogeneously. The aim of this work is to develop recommendations on the prevention and monitoring of cardiovascular events (CVD) in patients with CML treated with TKIs.


METHODS
Experts from the Spanish Group of Chronic Myeloid Leukemia together with experts in cardiovascular risk have elaborated, after a consensus meeting, recommendations for the prevention and follow-up of CVE in patients with CML treated with TKI.


RESULTS
Recommendations regarding the necessary information to be collected on clinical history, treatment decisions, as well as treatment and monitoring of CVRFs are shown in this document.


CONCLUSIONS
TKI treatment requires comprehensive patient management from a multidisciplinary approach, in which both the prevention and management of CVRFs are essential.
Servicio de Hematología, Hospital Universitario Ramón y Cajal, Madrid, España. Electronic address: jvalentingg@gmail.com.
Valentín
V
García-Gutiérrez
Servicio de Hematología, Hospital Regional Universitario Carlos Haya, Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España.
Antonio
A
Jiménez-Velasco
Servicio de Hematología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Las Palmas, España.
M Teresa
MT
Gómez-Casares
Servicio de Hematología, Instituto de Investigación Biomédica de Salamanca (IBSAL)-Hospital Universitario de Salamanca, Salamanca, España.
Fermín
F
Sánchez-Guijo
Servicio de Cardiología, Hospital Universitario La Paz, Madrid, España.
Jose Luis
JL
López-Sendón
Servicio de Hematología, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria (IIS-IP), Madrid, España.
Juan Luis
JL
Steegmann Olmedillas
D000359:Aftercare / Q000379:methods; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D000069439:Dasatinib / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors
D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C498826:nilotinib; D000069439:Dasatinib
Cardiovascular risk factors; Chronic myeloid leukemia; Comprehensive treatment; Conferencia de consenso; Consensus meeting; Factores de riesgo cardiovascular; Leucemia mieloide crónica; Tratamiento integral